Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2043 Neoplasms 1458 Carcinoma, Non-Small-Cell Lung 1360 Prostatic Neoplasms 1104 Multiple Myeloma 870 Leukemia, Myeloid, Acute 767 Colorectal Neoplasms 710 Neoplasm Metastasis 702 Lung Neoplasms 696 Melanoma 683 Lymphoma 665 Leukemia 595 Lymphoma, Non-Hodgkin 592 Leukemia, Lymphocytic, Chronic, B-Cell 535 Ovarian Neoplasms 530 Pancreatic Neoplasms 500 Precursor Cell Lymphoblastic Leukemia-Lymphoma 483 Recurrence 474 Myelodysplastic Syndromes 424 Lymphoma, Follicular 418 Carcinoma, Renal Cell 410 Head and Neck Neoplasms 407 Glioblastoma 380 Lymphoma, Large B-Cell, Diffuse 379 Brain Neoplasms 374 Hodgkin Disease 354 Carcinoma, Hepatocellular 332 Squamous Cell Carcinoma of Head and Neck 326 Lymphoma, Mantle-Cell 306 Sarcoma 286

Interventions

Sugars 1 Donepezil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Memory Disorders × Clear all

NCT02822573 2023-09-13

Remember

Wake Forest University Health Sciences

Phase 3 Completed

276 enrolled 33 charts

Breast Neoplasms, Memory Disorders, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡